Longeviti Neuro Solutions, a neurotechnology company with a focus on innovative platform solutions for complex brain ...

Our lead product candidate, Halneuron ®, is in Phase 2b development as a non-opioid, Na V 1.7 inhibitor to treat pain conditions including the neuropathic pain associated with chemotherapy treatment.

Maxim Group LLC (“Maxim”) acted as the sole Book-Running manager for the Offering. Loeb & Loeb LLP acted as counsel to the Company, and Ellenoff Grossman & Schole LLP acted as counsel to Maxim for the ...

CAMBRIDGE, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- SurgiBox, a medical technology company committed to improving access to safe, clean surgery at the point of need, announced today it has received ...

CT-155 (BI 3972080) is an investigational prescription digital therapeutic that aims to provide interactive psychosocial intervention techniques as an adjunct to standard antipsychotic therapy to ...

SOUTH JORDAN, Utah, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced the US commercial release of the Prelude ...

“Recovery Brands has been a trusted digital front door to treatment for millions, and this strategic sale enables Recovery.com to scale that impact even further—while allowing AAC to sharpen its focus ...

As WeightWatchers evolves its holistic model of care, community will continue to play an increasingly vital role, given its impact on long-term health outcomes and sustained behavioral change. In this ...

TEASE-3, the first clinical trial in early-stage Stargardt disease, is an open-label study of gildeuretinol in genetically confirmed patients who exhibit early retinal changes on imaging but have not ...

Royalty revenue was $1,378 million in the first six months of 2025 compared to $1,111 million in the first six months of 2024, an increase of $267 million, or 24%. The increase in royalties was driven ...

The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in ...

Zealand Pharma conference call on August 14 at 2pm CET (8am ET) to present second quarter 2025 financial results ...